GlassScriptPhysician profile
John F Robinson
NPI 1396737052
$4,810.61
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,647 · 2020: $164.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,483.27 | 2019 | |
| Genentech USA, INC. | $168.66 | 2019 | |
| Merck Sharp & Dohme LLC | $149.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $138.11 | 2019 | |
| Janssen Biotech, INC. | $112.96 | 2019 | |
| Genzyme Corporation | $108.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $101.73 | 2019-2020 | |
| Seagen INC. | $86.45 | 2019 | |
| Pfizer INC. | $62.86 | 2019 | |
| Celgene Corporation | $61.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.54 | 2019 | |
| Astellas Pharma US INC | $37.39 | 2019 | |
| Daiichi Sankyo INC. | $27.97 | 2019 | |
| Tersera Therapeutics LLC | $25.24 | 2019 | |
| Lilly USA, LLC | $23.63 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $20.90 | 2019 | |
| Taiho Oncology, INC. | $19.08 | 2019 | |
| Heron Therapeutics, INC. | $18.79 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.56 | 2020 | |
| Glaxosmithkline, LLC. | $16.88 | 2020 | |
| Secura Bio, INC. | $16.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2019 | |
| Coherus Oncology, INC. | $14.36 | 2020 | |
| Kite Pharma, INC. | $14.30 | 2020 | |
| Exelixis INC. | $13.47 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.